|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease. Our vision is to develop and market products along a treatment continuum that cardiovascular disease consumers, healthcare professionals and specialized cardiovascular disease research and healthcare institutions will identify, recommend and seek.
Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.
Forbes Medi-Tech is listed on NASDAQ under FMTI & Toronto Stock Exchange under the symbol FMI.TO
Forbes Medi-Tech Receives FDA Clearance to Initiate US Phase II Trial for Cholesterol-Lowering Drug, FM-VP4
Forbes Medi-Tech Inc. (NASDAQ:FMTI)(TSX:FMI) announced that the FDA has informed Forbes that it may proceed with its Phase II clinical trial of its cholesterol-lowering drug, FM-VP4, as set forth in the Investigational New Drug Application (IND).
Forbes plans to initiate the US Phase II trial program later this month.
"This is a major milestone for the Company and further supports our commitment to the development of FM-VP4 and its potential as a cholesterol absorption inhibitor," said Charles Butt, President and CEO of Forbes Medi-Tech Inc. "I look forward to the initiation of this key clinical trial in FM-VP4's pharmaceutical development path."
FM-VP4 is a cholesterol absorption inhibitor, a new class in cholesterol-lowering drugs. FM-VP4 has demonstrated significant cholesterol-lowering and anti-atherosclerotic properties in pre-clinical studies. The cardiovascular market represents a significant opportunity as industry-wide sales of cardiovascular pharmaceuticals are estimated to grow to over $40 billion by 2011. (Datamonitor, 2004)
2005 AAPS Annual Meeting and Exposition 11/5/2005 - 11/10/2005
"We intend to proceed directly to a more definitive animal model study with FM-VP24. Additionally, we are evaluating strategic licensing solutions that may include an early partnership program. This strategy fits well with our intention to further diversify our drug development pipeline through potential M&A activities."
Twinlab product & Reducol
Cholesterol Success ( Reducol ), Twinlab, 120 Tabs
Cholesterol Success ( Reducol ), Twinlab, 60 Orange Chewable Wafers
Follw these directions. : Click the link above. : scroll to bottom of the page.
Dont click on functional food, dont click on more info.
Click on the reducol LOGO : when the new window pops up click on the slideshow
when it comes back to The first page you have to click one more time to see the SECRET PRODUCT LAUNCH
Fayrefield & Reducol - A Healthy Partnership
Heartfelt is the name to watch out for. Fayrefield, in partnership with Forbes Medi_Tech, will be at the heart of the UK health market. Fermented milk, spreads, milk drinks, yogurts & other popular foods.
Picture of Pirkka Yogurt with Reducol
pirkka.fi Nice to see a real product on the market.
Redulcol : reducol.com website
Forbes Medi-Tech Inc.'s latest innovation, Vivola™ Oil, is Functional Oil that has been clinically shown to maintain a healthy body weight and reduce Total and LDL-cholesterol (bad cholesterol), both important risk factors for coronary heart disease. This oil is composed of naturally-sourced ingredients and is suitable for cooking, baking and salad dressing. The Company is currently exploring licensing opportunities with possible partners accross the world for the sale and/or licensing of the "Vivola™ oil".
Forbes Medi-Tech Inc.
Darren Seed Manager, Investor Relations (604) 681-8976 email@example.com
Yahoo Finance has a message board for FMTI if you want to learn more.
Disclousure: Contains forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements.
The stock market has its ups & down so do your own research before you plan to buy, sell, hold or short.
If you choose to invest in a security that is mentioned on this thread, it is your obligation to thoroughly research that security and make a personal decision to buy or pass based on your investigation alone. The posters on this thread are only sharing their opinions and are in no way suggesting that you make any investment decision based on what is posted here.
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|